Early differentiating between the chemotherapy responders and nonresponders: preliminary results with ultrasonic spectrum analysis of the RF time series in preclinical breast cancer models

BACKGROUND: This study was aimed to assess whether ultrasonic spectrum analysis of radiofrequency (RF) time series using a clinical ultrasound system allows for early differentiating between the chemotherapy responders and nonresponders in human breast cancer xenografts that imitate clinical respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fei, Huang, Yini, Wang, Jianwei, Lin, Chunyi, Li, Qing, Zheng, Xueyi, Wang, Yun, Cao, Longhui, Zhou, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714306/
https://www.ncbi.nlm.nih.gov/pubmed/31462322
http://dx.doi.org/10.1186/s40644-019-0248-y
Descripción
Sumario:BACKGROUND: This study was aimed to assess whether ultrasonic spectrum analysis of radiofrequency (RF) time series using a clinical ultrasound system allows for early differentiating between the chemotherapy responders and nonresponders in human breast cancer xenografts that imitate clinical responding and nonresponding tumors. METHODS: Clinically responding (n = 20; MCF-7) and nonresponding (n = 20; MBA-MD-231) breast cancer xenografts were established in 40 nude mice. Ten mice from each group received either chemotherapy (adriamycin, 4 mg/kg) or saline as controls. Each tumor was imaged longitudinally with a clinical ultrasound scanner at baseline (day 0) and subsequently on days 2, 4, 6, 8 and 12 following treatment, and the corresponding RF time-series data were collected. Changes in six RF time-series parameters (slope, intercept, S1, S2, S3 and S4) were compared with the measurement of the tumor cell density, and their differential performances of the treatment response were analyzed. RESULTS: Adriamycin significantly inhibited tumor growth and decreased the cancer cell density in responders (P < 0.001) but not in nonresponders (P > 0.05). Fold changes of slope were significantly increased in responders two days after adriamycin treatment (P = 0.002), but not in nonresponders (P > 0.05). Early changes in slope on day 2 could differentiate the treatment response in 100% of both responders (95% CI, 62.9–100.0%) and nonresponders (95% CI, 88.4–100%). CONCLUSIONS: Ultrasonic RF time series allowed for the monitoring of the tumor response to chemotherapy and could further serve as biomarkers for early differentiating between the treatment responders and nonresponders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40644-019-0248-y) contains supplementary material, which is available to authorized users.

Ejemplares similares